236 related articles for article (PubMed ID: 15473127)
1. The effects of diet, sulfonylurea, and Repaglinide therapy on clinical and metabolic parameters in type 2 diabetic patients during Ramadan.
Sari R; Balci MK; Akbas SH; Avci B
Endocr Res; 2004 May; 30(2):169-77. PubMed ID: 15473127
[TBL] [Abstract][Full Text] [Related]
2. A comparison of glycemic effects of glimepiride, repaglinide, and insulin glargine in type 2 diabetes mellitus during Ramadan fasting.
Cesur M; Corapcioglu D; Gursoy A; Gonen S; Ozduman M; Emral R; Uysal AR; Tonyukuk V; Yilmaz AE; Bayram F; Kamel N
Diabetes Res Clin Pract; 2007 Feb; 75(2):141-7. PubMed ID: 16815586
[TBL] [Abstract][Full Text] [Related]
3. An open label comparative study of glimepiride versus repaglinide in type 2 diabetes mellitus Muslim subjects during the month of Ramadan.
Anwar A; Azmi KN; Hamidon BB; Khalid BA
Med J Malaysia; 2006 Mar; 61(1):28-35. PubMed ID: 16708731
[TBL] [Abstract][Full Text] [Related]
4. Repaglinide plus single-dose insulin glargine: a safe regimen for low-risk type 2 diabetic patients who insist on fasting in Ramadan.
Bakiner O; Ertorer ME; Bozkirli E; Tutuncu NB; Demirag NG
Acta Diabetol; 2009 Mar; 46(1):63-5. PubMed ID: 18825302
[TBL] [Abstract][Full Text] [Related]
5. Comparison between repaglinide and glimepiride in patients with type 2 diabetes mellitus: a one-year, randomized, double-blind assessment of metabolic parameters and cardiovascular risk factors.
Derosa G; Mugellini A; Ciccarelli L; Crescenzi G; Fogari R
Clin Ther; 2003 Feb; 25(2):472-84. PubMed ID: 12749508
[TBL] [Abstract][Full Text] [Related]
6. Repaglinide versus glibenclamide treatment of Type 2 diabetes during Ramadan fasting.
Mafauzy M
Diabetes Res Clin Pract; 2002 Oct; 58(1):45-53. PubMed ID: 12161056
[TBL] [Abstract][Full Text] [Related]
7. Repaglinide has more beneficial effect on cardiovascular risk factors than glimepiride: data from meal-test study.
Rizzo MR; Barbieri M; Grella R; Passariello N; Paolisso G
Diabetes Metab; 2005 Jun; 31(3 Pt 1):255-60. PubMed ID: 16142016
[TBL] [Abstract][Full Text] [Related]
8. Hypoglycemia in patients with type 2 diabetes from India and Malaysia treated with sitagliptin or a sulfonylurea during Ramadan: a randomized, pragmatic study.
Aravind SR; Ismail SB; Balamurugan R; Gupta JB; Wadhwa T; Loh SM; Suryawanshi S; Davies MJ; Girman CJ; Katzeff HL; Radican L; Engel SS; Wolthers T
Curr Med Res Opin; 2012 Aug; 28(8):1289-96. PubMed ID: 22738801
[TBL] [Abstract][Full Text] [Related]
9. The effect of vildagliptin relative to sulfonylurea as dual therapy with metformin (or as monotherapy) in Muslim patients with type 2 diabetes fasting during Ramadan in the Middle East: the VIRTUE study.
Hassoun AA; Al-Arouj M; Ibrahim M
Curr Med Res Opin; 2017 Jan; 33(1):161-167. PubMed ID: 27684469
[TBL] [Abstract][Full Text] [Related]
10. Impact of metformin versus the prandial insulin secretagogue, repaglinide, on fasting and postprandial glucose and lipid responses in non-obese patients with type 2 diabetes.
Lund SS; Tarnow L; Frandsen M; Smidt UM; Pedersen O; Parving HH; Vaag AA
Eur J Endocrinol; 2008 Jan; 158(1):35-46. PubMed ID: 18166815
[TBL] [Abstract][Full Text] [Related]
11. Metabolic effect of repaglinide or acarbose when added to a double oral antidiabetic treatment with sulphonylureas and metformin: a double-blind, cross-over, clinical trial.
Derosa G; Salvadeo SA; D'Angelo A; Ferrari I; Mereu R; Palumbo I; Maffioli P; Randazzo S; Cicero AF
Curr Med Res Opin; 2009 Mar; 25(3):607-15. PubMed ID: 19232035
[TBL] [Abstract][Full Text] [Related]
12. Effect of repaglinide and gliclazide on glycaemic control, early-phase insulin secretion and lipid profiles in.
Zhang H; Bu P; Xie YH; Luo J; Lei MX; Mo ZH; Liao EY
Chin Med J (Engl); 2011 Jan; 124(2):172-6. PubMed ID: 21362360
[TBL] [Abstract][Full Text] [Related]
13. A comparison of repaglinide and glibenclamide in the treatment of type 2 diabetic patients previously treated with sulphonylureas.
Landgraf R; Bilo HJ; Müller PG
Eur J Clin Pharmacol; 1999 May; 55(3):165-71. PubMed ID: 10379630
[TBL] [Abstract][Full Text] [Related]
14. Is Ramadan fasting safe in type 2 diabetic patients in view of the lack of significant effect of fasting on clinical and biochemical parameters, blood pressure, and glycemic control?
M'guil M; Ragala MA; El Guessabi L; Fellat S; Chraibi A; Chabraoui L; Israili ZH; Lyoussi B
Clin Exp Hypertens; 2008 Jul; 30(5):339-57. PubMed ID: 18633757
[TBL] [Abstract][Full Text] [Related]
15. Repaglinide is more efficient than glimepiride on insulin secretion and post-prandial glucose excursions in patients with type 2 diabetes. A short term study.
Rizzo MR; Barbieri M; Grella R; Passariello N; Barone M; Paolisso G
Diabetes Metab; 2004 Feb; 30(1):81-9. PubMed ID: 15029102
[TBL] [Abstract][Full Text] [Related]
16. A double-blind randomized comparison of meal-related glycemic control by repaglinide and glyburide in well-controlled type 2 diabetic patients.
Damsbo P; Clauson P; Marbury TC; Windfeld K
Diabetes Care; 1999 May; 22(5):789-94. PubMed ID: 10332683
[TBL] [Abstract][Full Text] [Related]
17. Effect of Switching from Sulphonylurea to Repaglinide Twice or Three Times Daily for 4 Months on Glycemic Control in Japanese Patients with Type 2 Diabetes.
Kamiyama H; Aoki K; Nakajima S; Shinoda K; Kamiko K; Taguri M; Terauchi Y
Intern Med; 2016; 55(13):1697-703. PubMed ID: 27374668
[TBL] [Abstract][Full Text] [Related]
18. [Ramadan fasting in type 2 diabetes mellitus].
Bouguerra R; Jabrane J; Maâtki C; Ben Salem L; Hamzaoui J; El Kadhi A; Ben Rayana C; Ben Slama C
Ann Endocrinol (Paris); 2006 Mar; 67(1):54-9. PubMed ID: 16596059
[TBL] [Abstract][Full Text] [Related]
19. Sulphonylureas in the management of type 2 diabetes during the fasting month of Ramadan.
Zargar A; Basit A; Mahtab H
J Indian Med Assoc; 2005 Aug; 103(8):444-6. PubMed ID: 16363203
[TBL] [Abstract][Full Text] [Related]
20. Modification of postprandial hyperglycemia with insulin lispro improves glucose control in patients with type 2 diabetes.
Feinglos MN; Thacker CH; English J; Bethel MA; Lane JD
Diabetes Care; 1997 Oct; 20(10):1539-42. PubMed ID: 9314631
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
